Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2017 call → NOWe need to determine if management's forward account is substantially about counterparties' own growth trajectories, with the company already embedded, and the trajectory early and large. The transcript: Acadia Healthcare, behavioral health facilities. Management discusses growth via bed additions, joint ventures, de novos, UK operations. They mention joint ventures with hospitals (Erlanger, Mount Carmel). They talk about the UK NHS transition, local areas determining patient flow, and that it will take another year. They mention the Cures Act money going through states, and they have lobbyists. They mention opioid treatment demand. Key question: Does management narrate what counterparties are doing and scaling, such that company's volume is a consequence? Counterparties could be hospitals (joint venture partners), NHS, states. But management's forward account is mostly about their own bed additions, labor management, de novos, and general demand. They mention joint ventures as growth strategy, but not detailed counterparty trajectories. They mention NHS transition as a factor, but it's a government process, not a counterparty scaling. They mention states implementing Cures Act money, but that's external funding, not a counterparty's own build-out. The company is not supplying a product to a customer that is scaling; it's providing healthcare services directly. The "counterparties" are payers and referral sources, not customers whose growth drives the company's volume in the sense of a supplier. The company's growth is driven by its own bed additions and market demand. The joint ventures are partnerships, but management doesn't describe the hospital partners' own expansion plans as the driver. They say they have two JVs opening, but that's the company's own initiative. So answer NO. Check conditions: (1) Management speaks about counterparties' business as part of its own? They mention NHS transition, but not as a counterparty scaling. They mention states implementing funds, but not as a trajectory. (2) Already inside? Not really. (3) Early and large? No. Thus NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.